Winton Group’s Apellis Pharmaceuticals APLS Stock Holding History

Winton Group’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-69,291	Closed	-$2.79M	–	1168
2026 Q1	$2.79M	Sell	69,291 -17,362	-20%	-$374K	0.1%	276
2025 Q4	$2.18M	Buy	+86,653	New	+$2.03M	0.08%	293
2022 Q4	–	Sell	-7,218	Closed	-$493K	–	912
2022 Q3	$493K	Buy	+7,218	New	+$427K	0.03%	647
2022 Q2	–	Sell	-9,931	Closed	-$505K	–	940
2022 Q1	$505K	Buy	+9,931	New	+$438K	0.03%	678

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Winton Group's APLS Position: Q2 2026 in Review

Winton Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 69,291 shares — an estimated $2.79M sold.

Winton Group first reported a position in APLS in Q1 2022 and held it in 4 quarters. The position peaked at $2.79M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Winton Group reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Winton Group sold 69,291 Apellis Pharmaceuticals shares in Q2 2026, an estimated $2.79M.
Winton Group first reported a position in Apellis Pharmaceuticals in Q1 2022 and held it in 4 quarters.
Winton Group's Apellis Pharmaceuticals position peaked at $2.79M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.